Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.
Zacks Investment Research on MSN1d
LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug ...
Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...
As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks ...
Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and ...
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...
Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...
Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...
Novo Nordisk is licensing Lexicon Pharmaceuticals experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...
Lexicon Pharmaceuticals (LXRX) announced that it has entered into an exclusive license agreement with Novo Nordisk (NVO) for LX9851, a ...
Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. Lexicon will be responsible for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback